Bayer's €2 Billion Hybrid Bond Sale Anchors a Busy Stretch of Dealmaking

Bayer priced €2 billion in 30-year hybrid notes, raising subordinated debt to €6.55 billion, days after Apollo and KKR agreed to invest €3 billion in its contraceptive unit.

Bayer moved to shore up the long end of its balance sheet on Wednesday, pricing €2 billion of hybrid notes in a two-tranche deal that lifts the German group's outstanding subordinated debt to €6.55 billion. The Leverkusen-based agricultural and pharmaceutical company split the issue into two €1 billion tranches, each carrying a 30-year maturity, with call options locked out for six and nine years respectively. Coupons were set at 5.75% and 6.25%.

The financing tool is a familiar one for Bayer: hybrid bonds count partly as equity, giving the company more room to maneuver with rating agencies while leaving existing shareholders' voting rights untouched. The proceeds extend the maturity profile of Bayer's obligations and hand management breathing space as loans come due.

Equity partners step into the contraception business

The bond sale lands just days after Apollo and KKR agreed to inject roughly €3 billion of equity into Bayer's long-acting reversible contraceptive franchise. Bayer retains both the entrepreneurial majority and operational control of that business under the arrangement.

Management is simultaneously trimming the pharmaceutical portfolio. Cancer drug Stivarga is being sold to Grünenthal for as much as €375 million, a deal contingent on regulatory clearances and targeted to close between late 2026 and early 2027.

From blister packs to soybean genetics

Elsewhere on the operational front, Bayer rolled out a new polypropylene mono-material blister package for its stomach remedy Talcid in Germany on Wednesday. The switch is designed to improve recyclability and will be extended to additional European markets in stages.

Research spending continues through Leaps by Bayer, the group's investment arm, which joined the Series A round of Robigo on September 17. The partnership targets biological crop protection, with a product against Sudden Death Syndrome in soybeans slated for market launch in 2028. Bayer's agriculture division also reported headway on gene-edited lodging-tolerant soybeans and an herbicide tolerance trait matched to the active ingredient Icafolin. In pharmaceuticals, a Phase II trial has begun for the GIRK4 inhibitor BAY 3670549 in atrial fibrillation.

Shareholder register shifts as analysts turn more bullish

Long-term investors have taken note of the steady reduction in uncertainty. Bayer shares have climbed 35% since the start of the year, recovering meaningfully from earlier lows. The stock traded at €49.90 on Wednesday, up 0.8% on the day.

Amundi has raised its voting stake in Bayer to 3.04%, crossing Germany's 3% disclosure threshold. Analyst James Gordon of Barclays lifted his price target on September 8 to €70 from €60 while keeping an "Overweight" rating, pointing to revaluation potential as the legal burden surrounding the glyphosate herbicide comes closer to resolution. A Missouri court heard arguments roughly two weeks ago on approving a settlement in the Roundup litigation, a deal that if cleared would spread payments over as many as 21 years.

Investors will get their next hard look at how these balance-sheet and strategic moves are feeding through on November 3, 2026, when Bayer publishes its third-quarter report.